Dr. Daniel J. Rader, M.D., FAHA, founded Vascular Strategies LLC. Dr. Rader serves as the Director of the Translational Research Center, Director of Preventive Cardiovascular Medicine and Lipid Clinic and the Director of the Lipid-Atherosclerosis Research Unit at the University of Pennsylvania. Dr. Rader serves as the Associate Director of Institute for Translational Medicine and Therapeutics at the University of Pennsylvania. He has over 22 years experience in preclinical lipoprotein metabolism, clinical trials of HDL, RCT and reversing atherosclerosis. Dr. Rader served as a Staff Scientist of the National Institutes of Health. He was recruited in 1994 to the University of Pennsylvania. He is the Chairman of Scientific Advisory Board at Omthera Pharmaceuticals, Inc. He serves as a Board Member at Vascular. Dr. Rader has been a Member of Scientific and Clinical Advisory Board of Dr. Reddy's Laboratories Ltd. since June 2005. He serves as a Director of Vascular Strategies LLC. He serves as a Member of Scientific Advisory Board at Alnylam Pharmaceuticals, Inc. Dr. Rader serves as a Member of Scientific Advisory Board for Quatrx Pharmaceuticals Company. He serves as a Member of Scientific Advisory Board of Aegerion Pharmaceuticals, Inc. He served as a Member of Clinical Advisory Board of Resverlogix Corp. Dr. Rader served as a Member of Medical Advisory Board of Atherotech Inc. Dr. Rader served as a Member of Medical & Scientific Advisory Board of FMI Holdings Ltd. (also known as Forbes Medi Tech Inc.) since February 19, 2004. He serves on the editorial boards of Arteriosclerosis Thrombosis and Vascular Biology Council, American Journal of Physiology (Endocrinology and Metabolism), Circulation, Circulation Research and Trends in Molecular Medicine and is a Reviewer for many journals, including Nature, Nature Medicine, Science, New England Journal of Medicine and Journal of Clinical Investigation. Dr. Rader is a Member of the American Society of Clinical Investigation. He was an Investigator of the American Heart Association. Dr. Rader is the Cooper-McClure Associate Professor of Medicine and Professor of Pathology and Pharmacology at the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. Dr. Rader has authored over 274 peer-reviewed publications, review articles and book chapters, including chapters on lipoprotein disorders for Harrison's Principles of Internal Medicine, Topol's Textbook of Cardiovascular Medicine and Nelson's Textbook of Pediatrics. He is an invited Speaker nationally and internationally on his basic and translational research in lipoprotein metabolism and atherosclerosis. He is a recipient of the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research and the Doris Duke Foundation Distinguished Clinical Scientist Award and a Bristol Myers Squibb "Freedom to Discover" Unrestricted Cardiovascular Research Grant. Dr. Rader's research focuses on genetic and pharmacologic regulation of lipoprotein metabolism and atherosclerosis, human genetics of lipid disorders and atherosclerosis, novel approaches to treatment of dyslipidemia and regression of atherosclerosis and HDL metabolism. He is a recognized expert. In 1988, he began a fellowship in lipid metabolism at the Molecular Disease Branch of the National Heart, Lung and Blood Institute of the National Institutes of Health. He completed an Internship and Residency in Internal Medicine at Yale-New Haven Hospital, followed by a year as a Chief Resident. Dr. Rader received his undergraduate degree from Lehigh University and his Medical degree from the Medical College of Pennsylvania.

 Internal Medicine